Max Barnhart
Verified
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Max
Contact Max, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
Polymyxins get a helping hand to defeat antimicrobial resistant pathogens
Polymyxins are a last-line-of-defense group of lipopeptide antibiotics that health-care workers turn to when other antimicrobials fail. But even these powerful drugs can lose their edge as bacteria gain resistance.
Ebola vaccine enters Phase 3 trial. But will it work on a new target?
Key Insights The Democratic Republic of the Congo is receiving 70,000 doses of the Ebola vaccine, Ervebo, in a Phase 3 clinical trial to determine the effectiveness of the vaccine against a species of Ebola that it wasn’t specifically designed to target. New evidence has emerged supporting the cross-reactivity of Ervebo against the Bundibugyo virus, which is responsible for the current outbreak. It’s not yet clear if Ervebo will be effective in the context of the current outbreak.
Modified DNA-origami method images transcription over time
In our cells, countless RNA polymerase (RNAP) enzymes zip along our DNA, rotating and twirling in an elaborate molecular dance that takes place at a nanometer scale. Few have observed this dance, but Pallav Kosuri, a biophysicist at the Salk Institute for Biological Studies, is one of those lucky few.
Actions
Get in touch with Max
Contact Max, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack